A/Prof Grace Kong
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
101 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Journal article
DISCO update: Diagnostic performance of 64 Cu-SARTATE compared to 68 Ga-DOTATATE in patients with known or suspected neuroendocrine tumors.
DOI: 10.1200/jco.2026.44.16_suppl.41742026
Journal article
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT.
DOI: 10.2967/jnumed.125.2719952026
Journal article
THU-248 Hepatocellular carcinoma imaging using prostate-specific membrane antigen positron emission tomography - The Hepa-SMART trial
DOI: 10.1016/s0168-8278(26)01303-62026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.002
RECENT SCHOLARLY WORKS
2025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Conference Proceedings
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.30022025
Conference Proceedings
2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
DOI: 10.1016/j.annonc.2025.08.30072025
Journal article
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
DOI: 10.1007/s00259-025-07235-w